|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-9-1
|
|
pubmed:abstractText |
In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults.Methods. A clinical trial was conducted to examine whether the vaccine vCP1452 would elicit a greater HIV-specific CTL response when given at a dose of 10(8.0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants).
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI46725,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI46747,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI46757,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI47976,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI47980,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI47985,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI47996,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI48001,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI48017,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI48021,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI48022,
http://linkedlifedata.com/resource/pubmed/grant/1U01 AI48023
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:AllenMaryM,
pubmed-author:BadenLindsey RLR,
pubmed-author:BlattnerWilliam AWA,
pubmed-author:ChiuYa-LinYL,
pubmed-author:CoreyLawrenceL,
pubmed-author:FerrariGuidoG,
pubmed-author:FreySharonS,
pubmed-author:FuchsJonathan DJD,
pubmed-author:GoepfertPaul APA,
pubmed-author:GurunathanSanjayS,
pubmed-author:HortonHelenH,
pubmed-author:KeeferMichael CMC,
pubmed-author:KoblinBeryl ABA,
pubmed-author:McElrathM JulianaMJ,
pubmed-author:MontefioriDavid CDC,
pubmed-author:NIAID HIV Vaccine Trials Network,
pubmed-author:SpearmanPaulP,
pubmed-author:TomarasGeorgia DGD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
192
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1249-59
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16136469-AIDS Vaccines,
pubmed-meshheading:16136469-Double-Blind Method,
pubmed-meshheading:16136469-Female,
pubmed-meshheading:16136469-HIV Antibodies,
pubmed-meshheading:16136469-HIV Seronegativity,
pubmed-meshheading:16136469-HIV-1,
pubmed-meshheading:16136469-Humans,
pubmed-meshheading:16136469-Interferon-gamma,
pubmed-meshheading:16136469-Male,
pubmed-meshheading:16136469-Recombinant Proteins,
pubmed-meshheading:16136469-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:16136469-Treatment Outcome,
pubmed-meshheading:16136469-Vaccination,
pubmed-meshheading:16136469-Vaccines, Synthetic,
pubmed-meshheading:16136469-Viral Proteins
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
|
|
pubmed:affiliation |
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-2050, USA. paulg@uab.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Research Support, N.I.H., Extramural
|
